Relay Therapeutics (RLAY)
(Delayed Data from NSDQ)
$7.63 USD
-0.36 (-4.51%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.62 -0.01 (-0.13%) 7:18 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RLAY 7.63 -0.36(-4.51%)
Will RLAY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RLAY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RLAY
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
RLAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
Other News for RLAY
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
Relay Therapeutics price target lowered by $1 at Barclays, here's why
Relay Therapeutics (RLAY) Gets a Buy from Barclays
First Week of March 2025 Options Trading For Relay Therapeutics (RLAY)